Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Rancho BioSciences ... integration of Omicsoft’s Array Suite with tranSMART . ... be able to send data in tranSMART to Array ... all versions of tranSMART including the new 1.2 release. ... visualization and storage for the analysis of high dimensional ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 “Rapid ... automation across the U.S., increasing unemployment, depressing American ... It is a Catch 22—we need automated ... this means fewer jobs,” says economist and corporate ... Pollina Corporate Top 10 Pro-Business States for 2014, ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a ... Kidney Cancer News. , Bill Bro, KCA CEO, says, ... by an international news organization. When we began using iReport ... This month’s program highlights news of an enzyme that is ... recent study. Kidney Cancer News also presents a report on ...
(Date:7/30/2014)... July 30, 2014 Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended June 30, 2014 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
Breaking Biology Technology:Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... PARK, N.C., Oct. 29 Pharmaceutical Strategic Initiatives® ... in the field of thrombosis and anticoagulation provided ... at a recent symposium held at the XXXIII ... held in Jerusalem, Israel on October 12, 2010. ...
... Oct. 29 Regenicin, Inc. (OTC Bulletin ... in the development of regenerative cell therapies to restore ... that the Company,s Chief Executive Officer, Randall McCoy and ... RetailInvestorConferences.com .DATE: , November 4, 2010TIME: , ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 2Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 3Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 4Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 5Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 6Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 7Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 8Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 9Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 10Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 11Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 12Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information 13Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management 2Regenicin to Present Live at RetailInvestorConferences.com on November 4th 2
(Date:7/31/2014)... effect in 1839, humankind has sought to further understand ... purposes. In a new research report published in the ... , scientists may have uncovered a new method ... a naturally occurring combination of lipids that have been ... and across speciessuggests that this specific natural combination of ...
(Date:7/31/2014)... are familiar with Hibiscus flowers- they are an ... are commonly planted in the landscape. Some, like ... endangered species. , Only a relatively few botanists ... an equally beautiful and intriguing related group of ... of Hibiscus". , Brother of Hibiscus species are ...
(Date:7/31/2014)... shown that marine noise can affect animal movement and ... of Bristol and Exeter and the cole Pratique des ... boat noise stops embryonic development and increases larval mortality ... slug Stylocheilus striatus used in this study) ... later feed on toxic alga but this study, conducted ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Brother of Hibiscus is found alive and well on Maui 2Boat noise impacts development and survival of sea hares 2
... University of Florida study following the evolution of lice ... ago, a technology which enabled them to successfully migrate ... associate curator of mammals at the Florida Museum of ... modern humans to better understand human evolution and migration ...
... Calif.) Calling the results "extremely surprising," researchers from ... University report that methane gas concentrations in the Gulf ... months after a massive release occurred following the Deepwater ... study, led by oceanographers John Kessler of Texas A&M ...
... a significant step forward in understanding the atmosphere,s ... some other gases, except carbon dioxide. The issue ... studies suggesting the self-cleaning power of the atmosphere ... others suggest greater stability. And what researchers are ...
Cached Biology News:UF study of lice DNA shows humans first wore clothes 170,000 years ago 2UF study of lice DNA shows humans first wore clothes 170,000 years ago 3UCSB, Texas A&M scientists find methane gas concentrations have returned to near-normal levels 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... a recombinant human protein produced in E. coli ... RNase A type enzymes. The mode of ... in a 1:1 ratio. The enzyme has been ... and cell types. Addition of the ribonuclease inhibitor ...
... Recombinant RNasin Ribonuclease Inhibitors have broad spectrum ... eukaryotic RNases of the neutral type (1). ... by noncovalently binding to RNases in a ... binding of RNasin Ribonuclease Inhibitor to RNase ...
... acids ,The GC-RICH PCR System, a ... proofreading polymerase, powers through templates that are ... polymerases and other blends of polymerases. The ... unique GC-RICH Resolution Solution combine to deliver ...
Biology Products: